|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003864,
umls-concept:C0007301,
umls-concept:C0022742,
umls-concept:C0029408,
umls-concept:C0030705,
umls-concept:C0205098,
umls-concept:C0206015,
umls-concept:C0243125,
umls-concept:C0246719,
umls-concept:C0409959,
umls-concept:C0439834,
umls-concept:C0449258,
umls-concept:C0547047,
umls-concept:C0678594,
umls-concept:C0699900,
umls-concept:C1185625,
umls-concept:C1274040,
umls-concept:C1457887,
umls-concept:C2603343
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2006-12-4
|
|
pubmed:abstractText |
Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal models and have decreased pain in states of high bone turnover. The Knee OA Structural Arthritis (KOSTAR) study, which is the largest study to date investigating a potential structure-modifying OA drug, tested the efficacy of risedronate in providing symptom relief and slowing disease progression in patients with knee OA.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:AdamiSilvanoS,
pubmed-author:BearyJohn FJF,
pubmed-author:BinghamClifton OCO3rd,
pubmed-author:Buckland-WrightJ ChrisJC,
pubmed-author:ClauwDaniel JDJ,
pubmed-author:ClineGary AGA,
pubmed-author:CohenStanley BSB,
pubmed-author:DougadosMaximeM,
pubmed-author:GarneroPatrickP,
pubmed-author:MeyerJoan MJM,
pubmed-author:PelletierJean-PierreJP,
pubmed-author:RaynauldJean-PierreJP,
pubmed-author:SimonLee SLS,
pubmed-author:SpectorTimothy DTD,
pubmed-author:StrandVibekeV
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3494-507
|
|
pubmed:dateRevised |
2007-5-1
|
|
pubmed:meshHeading |
pubmed-meshheading:17075851-Adult,
pubmed-meshheading:17075851-Aged,
pubmed-meshheading:17075851-Aged, 80 and over,
pubmed-meshheading:17075851-Biological Markers,
pubmed-meshheading:17075851-Bone Density Conservation Agents,
pubmed-meshheading:17075851-Cartilage,
pubmed-meshheading:17075851-Disease Progression,
pubmed-meshheading:17075851-Etidronic Acid,
pubmed-meshheading:17075851-Female,
pubmed-meshheading:17075851-Humans,
pubmed-meshheading:17075851-Male,
pubmed-meshheading:17075851-Middle Aged,
pubmed-meshheading:17075851-Osteoarthritis, Knee,
pubmed-meshheading:17075851-Pain,
pubmed-meshheading:17075851-Placebos,
pubmed-meshheading:17075851-Severity of Illness Index,
pubmed-meshheading:17075851-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.
|
|
pubmed:affiliation |
Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA. Clifton.bingham@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
